ArticlePharmaceuticals (Basel, Switzerland)2013
RNAi Therapeutic Platforms for Lung Diseases.
Article in Pharmaceuticals (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 97 citations in OpenAlex.
- Optimization of Therapeutic modRNA Delivery to the Lung for Prevention of Pulmonary Fibrosis.Pharmaceutics · 2026Article
- RNA-Loaded Nanoparticles for Targeted Lung Delivery.Biomedicines · 2026Review
- Antioxidant, anti-inflammatory, and immunomodulatory pathways ofFrontiers in nutrition · 2026Article
- Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).Current drug delivery · 2025Review
- RNA Vaccines: Yeast as a Novel Antigen Vehicle.Vaccines · 2023Review
- Review
- Air Pollution and microRNAs: The Role of Association in Airway Inflammation.Life (Basel, Switzerland) · 2023Review
- Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.Pharmaceutical research · 2023Review
- Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.Acta pharmaceutica Sinica. B · 2023Review
- PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases.International journal of molecular sciences · 2023Review
- Aberrant methylation of Serpine1 mediates lung injury in neonatal mice prenatally exposed to intrauterine inflammation.Cell & bioscience · 2022Article
- Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.Acta pharmaceutica Sinica. B · 2022Review
- Targeting COPD with PLGA-Based Nanoparticles: Current Status and Prospects.BioMed research international · 2022Review
- Effects of sterol derivatives in cationic liposomes on biodistribution and gene-knockdown in the lungs of mice systemically injected with siRNA lipoplexes.Molecular medicine reports · 2021Article
- MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak.Journal of translational medicine · 2021Review
- Review
- Composition and Clinical Significance of Exosomes in Tuberculosis: A Systematic Literature Review.Journal of clinical medicine · 2021Review
- Nucleic acid-based therapy for coronavirus disease 2019.Heliyon · 2020Review
- Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases.Molecular therapy. Nucleic acids · 2019Review
- RNAi therapeutic strategies for acute respiratory distress syndrome.Translational research : the journal of laboratory and clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi) is rapidly becoming an important method for analyzing gene functions in many eukaryotes and holds promise for the development of therapeutic gene silencing. The induction of RNAi relies on small silencing RNAs, which affect specific messenger RNA (mRNA) degradation. Two types of small RNA molecules, i.e. small interfering RNAs (siRNAs) and microRNAs (miRNAs), are central to RNAi. Drug discovery studies and novel treatments of siRNAs are currently targeting a wide range of diseases, including various viral infections and cancers. Lung diseases in general are attractive targets for siRNA therapeutics because of their lethality and prevalence. In addition, the lung is anatomically accessible to therapeutic agents via the intrapulmonary route. Recently, increasing evidence indicates that miRNAs play an important role in lung abnormalities, such as inflammation and oncogenesis. Therefore, miRNAs are being targeted for therapeutic purposes. In this review, we present strategies for RNAi delivery and discuss the current state-of-the-art RNAi-based therapeutics for various lung diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.